biostudies-literatureXu AZhejiang Province Chinese Medicine Science Research Fund ProjectInstitution from Key Laboratory of Functional Molecular Imaging of Tumor and Interventional Diagnosis and Treatment of Shaoxing CityMedical and Health Research Project of Zhejiang Province872https://www.ebi.ac.uk/biostudies/studies/S-EPMC9364617biostudies-literatureUnknown22(1)<h4>Background</h4>The determination of HER2 expression status contributes significantly to HER2-targeted therapy in breast carcinoma. However, an economical, efficient, and non-invasive assessment of HER2 is lacking. We aimed to develop a clinicoradiomic nomogram based on radiomics scores extracted from multiparametric MRI (mpMRI, including ADC-map, T2W1, DCE-T1WI) and clinical risk factors to assess HER2 status.<h4>Methods</h4>We retrospectively collected 214 patients with pathologically confirmed invasive ductal carcinoma between January 2018 to March 2021 from Fudan University Shanghai Cancer Center, and randomly divided this cohort into training set (n = 128, 42 HER2-positive and 86 HER2-negative cases) and validation set (n = 86, 28 HER2-positive and 58 HER2-negative cases) at a ratiBMC cancerDevelopment and validation of a clinicoradiomic nomogram to assess the HER2 status of patients with invasive ductal carcinoma.PMC93646172021KY1161 and 2022KY13162021ZA138Zheng JXu ALi FWeng XChu XLv SShi DZhang SfalseDevelopment and validation of a clinicoradiomic nomogram to assess the HER2 status of patients with invasive ductal carcinoma.<h4>Background</h4>The determination of HER2 expression status contributes significantly to HER2-targeted therapy in breast carcinoma. However, an economical, efficient, and non-invasive assessment of HER2 is lacking. We aimed to develop a clinicoradiomic nomogram based on radiomics scores extracted from multiparametric MRI (mpMRI, including ADC-map, T2W1, DCE-T1WI) and clinical risk factors to assess HER2 status.<h4>Methods</h4>We retrospectively collected 214 patients with pathologically confirmed invasive ductal carcinoma between January 2018 to March 2021 from Fudan University Shanghai Cancer Center, and randomly divided this cohort into training set (n = 128, 42 HER2-positive and 86 HER2-negative cases) and validation set (n = 86, 28 HER2-positive and 58 HER2-negative cases) at a rati2022-01-01T00:00:00Z2022 Aug2025-04-04T13:46:30.56Z2025-04-04T13:46:30.56ZS-EPMC93646173594552610.1186/s12885-022-09967-6